Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Co. Ltd.

43.15
USD
+1.44
(+3.44%)
0.16EPS
227.91P/E
59.63BMarket Cap
Jan 28Next Earn

Total Valuation

USD

As of September 30, 2026, Takeda Pharmaceutical Co., Ltd. carries a market capitalization of 59.63B, placing it among publicly traded companies globally. Its enterprise value stands at 85.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap59.63B
Enterprise Value85.83B

Important Dates

Takeda Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for January 28, 2027.

Earnings Date1/28/2027

Share Statistics

As of September 30, 2026, Takeda Pharmaceutical Co., Ltd. has 1.60B shares outstanding.

Shares Outstanding1.60B

Valuation Ratios

As of September 30, 2026, Takeda Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 227.91. The price-to-sales ratio is 1.98, and the price-to-book ratio stands at 1.27.

PE Ratio227.91
PS Ratio1.98
PB Ratio1.27
P/TBV Ratio-6.31
P/FCF Ratio21.67
P/OCF Ratio10.57

Enterprise Valuation

As of September 30, 2026, Takeda Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 16.05 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.88 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 84.73 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 85.83B versus a market cap of 59.63B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.88
EV / EBITDA16.05
EV / EBIT84.73

Financial Position

As of September 30, 2026, Takeda Pharmaceutical Co., Ltd. maintains a current ratio of 1.15, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 61.69, indicating elevated leverage, while an interest coverage ratio of 9.89 demonstrates adequate ability to service its debt obligations.

Current Ratio1.15
Quick Ratio0.52
Debt / Equity61.69
Debt / EBITDA5.44
Interest Coverage9.89

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, Takeda Pharmaceutical Co., Ltd. posted a return on equity (ROE) of 0.56, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.27, measuring how efficiently the asset base is converted into earnings. The company generates approximately 632,786.97 in revenue per employee across its workforce of 47,135.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.17 indicates how many times Takeda Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)0.56
Return on Assets (ROA)0.27
Revenue Per Employee632,786.97
Employee Count47,135.50
Inventory Turnover1.17

Taxes

USD

Over the twelve months ended September 30, 2026, Takeda Pharmaceutical Co., Ltd. recorded an income tax benefit of -276.53M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -15.70M and 259.26M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-276.53M

Stock Price Statistics

USD

As of the close on November 12, 2026, Takeda Pharmaceutical Co., Ltd.'s stock has gained approximately 53.59% over the past 52 weeks. The 50-day moving average sits at 36.34, while the 200-day moving average is 31.09.

52-Week Price Change53.59%
50-Day Moving Average36.34
200-Day Moving Average31.09

Income Statement

USD

Over the twelve months ended September 30, 2026, Takeda Pharmaceutical Co., Ltd. generated 29.83B in revenue and converted that into 259.26M in net income, yielding earnings per share of 0.16. EBITDA reached 5.35B, while operating income came in at 4.43B.

Revenue29.83B
Gross Profit19.62B
Operating Income4.43B
Pretax Income-15.70M
Net Income259.26M
EBITDA5.35B
EBIT1.01B
Earnings Per Share (EPS)0.16

Balance Sheet

USD

As of September 30, 2026, Takeda Pharmaceutical Co., Ltd. holds 2.89B in cash and equivalents against 29.08B in total debt, resulting in a net debt position of 26.42B. Total book value stands at 47.13B, with working capital of 2.50B providing operational flexibility.

Cash & Cash Equivalents2.89B
Total Debt29.08B
Net Debt26.42B
Equity (Book Value)47.13B
Book Value Per Share29.50
Working Capital2.50B

Cash Flow

USD

Takeda Pharmaceutical Co., Ltd. produced 5.59B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -2.83B in capital expenditures, free cash flow totaled 2.76B - equivalent to 1.74 per share.

Operating Cash Flow5.59B
Capital Expenditures-2.83B
Free Cash Flow2.76B
FCF Per Share1.74

Margins

Over the twelve months ended September 30, 2026, Takeda Pharmaceutical Co., Ltd. posted a gross margin of 65.79, reflecting its pricing power and cost economics. The operating margin of 14.86 and net profit margin of 0.87 provide insight into operational efficiency.

Gross Margin65.79
Operating Margin14.86
Pretax Margin-0.05
Profit Margin0.87
EBITDA Margin17.93

Dividends & Yields

USD

Over the twelve months ended September 30, 2026, Takeda Pharmaceutical Co., Ltd. paid dividends of 1.27 per share. The dividend payout ratio of 764.63 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.61, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 8.11, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Takeda Pharmaceutical Co., Ltd. shareholders.

Dividend Per Share1.27
Payout Ratio764.63
Shareholder Yield8.11
FCF Yield4.61

Stock Splits

Takeda Pharmaceutical Co., Ltd.'s most recent stock split took place on March 28, 1988 with a 10:11 split ratio.

Last Split Date3/28/1988
Split Ratio10:11

Scores

As of September 30, 2026, Takeda Pharmaceutical Co., Ltd. has an Altman Z-Score of 2.08, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.08